INT35140

Context Info Confidence 0.32 First Reported 1981 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 7 Total Number 9 Disease Relevance 3.78 Pain Relevance 1.51

signal transduction (ANGPTL5) extracellular space (ANGPTL5) extracellular region (ANGPTL5)

Anatomy Link Frequency synovial fluid 2 cleavage 1 platelet 1 urine 1 ANGPTL5 (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammatory mediators 9 98.60 Inflammation 93 96.64 cocaine 140 90.72 chemokine 9 88.80 spinal inflammation 2 88.32 cytokine 15 87.60 rheumatoid arthritis 28 86.16 antagonist 1 79.12 peptic ulcer disease 1 74.76 adenocard 2 60.72

Disease Link Frequency Relevance Heat Disease 193 99.80 INFLAMMATION 106 98.40 Coagulation Disorder 12 91.12 Cryoglobulinemia 2 89.84 Low Back Pain 2 88.32 Systemic Lupus Erythematosus 4 87.36 Rheumatoid Arthritis 28 86.16 Thrombosis 17 85.24 Acute Coronary Syndrome 8 83.56 Mucocutaneous Lymph Node Syndrome 150 83.16

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Fibrinogen or fibrinogen degradation products were frequently present in synovial fluid cryoprecipitates but rarely in serum cryoprecipitates.

Protein_catabolism (degradation) of fibrinogen in synovial fluid

1) Confidence 0.32 Published 1981 Journal Arthritis Rheum. Section Abstract Doc Link 7317115 Disease Relevance 0.50 Pain Relevance 0.17

Fibrinogen or fibrinogen degradation products were frequently present in synovial fluid cryoprecipitates but rarely in serum cryoprecipitates.

Protein_catabolism (degradation) of Fibrinogen in synovial fluid

2) Confidence 0.32 Published 1981 Journal Arthritis Rheum. Section Abstract Doc Link 7317115 Disease Relevance 0.50 Pain Relevance 0.17

In contrast to previously described paraproteins, this patient's IgG appeared to inhibit the activity of thrombin per se rather than to interfere with fibrinogen cleavage or fibrin polymerization.

Protein_catabolism (cleavage) of fibrinogen in cleavage

3) Confidence 0.13 Published 1987 Journal Am. J. Hematol. Section Abstract Doc Link 3578266 Disease Relevance 0.40 Pain Relevance 0.07

The results indicate that cPUK exerts fibrinolytic efficacy without systemic plasminogen activation and breakdown of fibrinogen.

Protein_catabolism (breakdown) of fibrinogen

4) Confidence 0.11 Published 1987 Journal Arzneimittelforschung Section Abstract Doc Link 3118890 Disease Relevance 0 Pain Relevance 0

Fibrinogen is degraded by MMP9 [39–41], and the fibrinogen degradation fragments have been shown to be biologically important molecules with numerous pro-inflammatory actions [42].

Protein_catabolism (degraded) of Fibrinogen associated with inflammation

5) Confidence 0.10 Published 2010 Journal Clin Proteomics Section Body Doc Link PMC2970804 Disease Relevance 0.50 Pain Relevance 0.22

We reasoned that the generation of the SJIA urine biomarker peptides, including those derived from fibrinogen, may be an outcome of the actions of inflammatory mediators on protease expression and regulation, generating a disease-specific degradation pattern of source proteins, such as fibrinogen.

Protein_catabolism (degradation) of fibrinogen in urine associated with inflammatory mediators and disease

6) Confidence 0.09 Published 2010 Journal Clin Proteomics Section Body Doc Link PMC2970804 Disease Relevance 0.58 Pain Relevance 0.25

The biochemical pathway for thrombolysis is such that tissue plasminogen activator coverts plaminogen to plasmin which in turn causes fibrinolysis by degrading fibrinogen and fibrin clots.

Protein_catabolism (degrading) of fibrinogen

7) Confidence 0.08 Published 2007 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2042971 Disease Relevance 0.41 Pain Relevance 0.35

Fibrinogen is degraded by MMP9 [39–41], and the fibrinogen degradation fragments have been shown to be biologically important molecules with numerous pro-inflammatory actions [42].

Protein_catabolism (degradation) of fibrinogen associated with inflammation

8) Confidence 0.07 Published 2010 Journal Clin Proteomics Section Body Doc Link PMC2970804 Disease Relevance 0.50 Pain Relevance 0.23

Abciximab, a platelet GP IIb/IIIa receptor blocker, was developed by Coller in 1985 and named 7E3.8 Abciximab is a chimeric human monoclonal antibody and binds to platelet surface GP IIb/IIIa receptors competitively with adhesive molecules, such as fibrinogen and von Willebrand factor, and blocks the final stage of platelet aggregation.9

Protein_catabolism (as) of fibrinogen in platelet

9) Confidence 0.01 Published 2008 Journal Yonsei Medical Journal Section Body Doc Link PMC2615343 Disease Relevance 0.38 Pain Relevance 0.04

General Comments

This test has worked.